|2022||National external quality assessment and direct method comparison reflect crucial deviations of Procalcitonin measurements in Germany.|
Masetto T, Eidizadeh A, Peter C, Grimmler M.
|2021||Letter to the Editor regarding “Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration”.|
Tölke SA, Masetto T, Grimmler M, Bindila L, Schneider K.
|2021||Evaluation of the necessity and the feasibility of the standardization of procalcitonin measurements: Activities of IFCC WG-PCT with involvement of all stakeholders.|
Huynh HH, Bœuf A, Vinh J, Delatour V; IFCC Working Group on Standardization of Procalcitonin assays (WG-PCT).
|2020||Bioanalytical Performance of a New Particle-Enhanced Method for Measuring Procalcitonin|
Dupuy AM, Bargnoux AS, Larcher R, Merindol A, Masetto T, Badiou S, Cristol JP
Evaluation of a new accurate and reliable particle enhanced immunoturbidimetric assay for the detection of Procalcitonin in the management of sepsis
The Third International Consensus Definitions for Sepsis and Septic Shock redefined sepsis as the life-threatening organ dysfunction caused by a dysregulated host response to infection. Sepsis is considered as a major public healthcare issue affecting more than 30 million people worldwide, associated with a mortality of potentially 6 million people and accounts for almost $24 billion in health care expenditures only in the US, annually. As the quick and accurate sepsis management reduces a possible negative clinical course and the economic burden, a multiplicity of plasma biomarker have been developed to overcome the long turn-around time of the blood culture. [...]